Study Evaluating Persistence Of Antibody Response Elicite... | NCT01025336

ID	Type	Description	Link
B1851029

Study Evaluating Persistence Of Antibody Response Elicite... | NCT01025336 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
23vPS Naive	Other	Group 1.1 13vPnC/13vPnC Group 1.2 13vPnC/23vPS Group 2 23vPS/13vPNC	Other: Blood draw
Prior 23vPS>/= 5 years	Other	Group 1 13vPnC/13vPnC Group 2 23vPS/13vPnC	Other: Blood draw

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Blood draw	Other	Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CIs) for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers.	Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CIs) for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers.	Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Secondary Outcomes

Measure	Description	Time Frame
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Contacts/Locations Module

Name	Affiliation	Role
Pfizer CT.gov Call Center	Pfizer	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Pfizer Investigational Site		Chandler	Arizona	85224	United States
Pfizer Investigational Site

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
30648932	Derived	Schmoele-Thoma B, van Cleeff M, Greenberg RN, Gurtman A, Jones TR, Sundaraiyer V, Gruber WC, Scott DA. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Hum Vaccin Immunother. 2019;15(3):575-583. doi: 10.1080/21645515.2018.1538618. Epub 2019 Jan 16.

Label	URL
To obtain contact information for a study center near you, click here.	View source

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23-valent pneumococcal polysaccharide vaccine (23vPS) prior to enrollment into the parent study (NCT00574548), completed study NCT00574548 receiving 13 valent pneumococcal conjugate (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Arm/Group Information

ID	Title	Description
BG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23-valent pneumococcal polysaccharide vaccine (23vPS) prior to enrollment into the parent study (NCT00574548), completed study NCT00574548 receiving 13 valent pneumococcal conjugate (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
BG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
BG002	23vPS/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
BG003	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants aged 70 years of age or greater previously vaccinated with 23vPS greater than or equal to (≥) 5 years before enrollment in the parent study (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
BG004	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants aged 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
BG005	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age Continuous

Mean

Standard Deviation

Years

Title

Denominators

Categories

Title	Measurements
	BG00064.0± 1.4 BG00164.1± 1.4 BG00264.2± 1.4 BG003

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG00076 BG001125 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)

Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CIs) for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers.

All-Available Immunogenicity Population included all participants enrolled in 6115A1-3018 (NCT01025336) with a valid and determinate assay result who received both vaccinations in either parent study 6115A1-3010 (NCT00574548) or 6115A1-3005 (NCT00546572). N=number of participants with valid and determinate antibody titer for the specified serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPs Naïve)	Participants aged 60 to 64 years old who had never received 23-valent pneumococcal polysaccharide vaccine (23vPS) prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13 valent pneumococcal conjugate (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A-3010 6115A1-3010(NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
OG002	23vPS/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Units	Counts
Participants	OG000129 OG001209 OG002179

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00054(40.8 to 71.0) OG00152(40.9 to 65.5) OG00236(27.1 to 46.7)

Serotype 3

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)

Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

All-Available Immunogenicity Population; N=number of participants with valid and determinate assay result for specified serotype at both 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 1/Year 1 (Parent study/NCT00574548), Month 1/Year 2 (Follow-up Study/NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)

Posted

Geometric Mean

95% Confidence Interval

titer

Month 1/Year 1 (Parent study/NCT00546572), Month 1/Year 2 (Follow-up Study/NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1)and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population; N=number of participants with valid and determinate assay result for specified serotype at both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)

All-Available Immunogenicity Population. N=number of participants with valid and determinate assay results for the specified serotype at both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with valid and determinate assay results for the specified serotype at both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 1/Year 0 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

Posted

Geometric Mean

95% Confidence Interval

titer

Month 1/Year 0 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with valid and determinate assay results for the specified serotype at both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 0 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 0 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/23vPS 1 Year After Vaccination 2 Compared to 23vPS 1 Year After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00574548), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
OG001	23vPS (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2).

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 23vPS/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC 1 Year After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00574548), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	23vPS/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
OG001	13vPnC (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and either 13vPnC or 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2) (both 13vPnC/13vPnC and 13vPnC/23vPS dose groups)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00574548), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)

Units	Counts
Participants	OG000

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 23vPS/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC 1 Year After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00546572), Month 1/Year 2 (Baseline; Follow-up Study NCT01025336)

ID	Title	Description
OG000	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)
OG001	13vPnC (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00546572), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)

Units	Counts
Participants	OG000

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC 1 Year After Vaccination 1 Compared to 23vPS 1 Year After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00574548)

ID	Title	Description
OG000	13vPnC (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study 6115A1-3010 (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1)
OG001	23vPS (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study (6115A1-3010 NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1)

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC 1 Year After Vaccination 1 Compared to 23vPS 1 Year After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 0/Year 1 (Parent Study NCT00546572)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Primary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)

All-Available Immunogenicity Population. N=number of participants with valid and determinate antibody titer for the specified serotype.

Posted

Geometric Mean

95% Confidence Interval

titer

Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

ID	Title	Description
OG000	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)
OG001	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants at least 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study 6115A1-3005 (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)

Arm/Groups

ID	Title	Description	Serious Events (At Risk)	Other Events (At Risk)
EG000	13vPnC/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23-valent pneumococcal polysaccharide vaccine (23vPS) prior to enrollment into the parent study (NCT00574548), completed study NCT00574548 receiving 13 valent pneumococcal conjugate (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)	130	130
EG001	13vPnC/23vPS Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)	210	210
EG002	23vPS/13vPnC Group (23vPS Naïve)	Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)	179	179
EG003	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants aged 70 years of age or greater previously vaccinated with 23vPS greater than or equal to (≥) 5 years before enrollment in the parent study (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)	221	221
EG004	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Participants aged 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)	222	222

Ancestor Terms

ID	Term
D013048	Specimen Handling
D019411	Clinical Laboratory Techniques
D019937	Diagnostic Techniques and Procedures
D003933	Diagnosis
D011677	Punctures
D013514	Surgical Procedures, Operative
D008919	Investigative Techniques

Title

Denominators

Categories

Serotype 1, 1 Month Post Vax 2

Title	Measurements
	OG000141(110.4 to 179.7) OG001149(123.5 to 180.6) OG00270(53.4 to 91.2)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00054(40.7 to 70.4) OG00152(41.1 to 66.1) OG00236(27.6 to 47.9)

Serotype 3, 1 Month Post Vax 2

Title	Measurements
	OG00087(73.7 to 103.8) OG001130(112.8 to 150.3) OG00250(40.2 to 63.1)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00018(14.6 to 22.9) OG00127(22.2 to 32.5) OG00218(14.5 to 22.2)

Serotype 4, 1 Month Post Vax 2

Title	Measurements
	OG0001284(992.3 to 1661.9) OG0011375(1137.0 to 1663.8) OG002898(684.1 to 1179.5)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000318(220.9 to 458.7) OG001369(276.1 to 493.9) OG002203(142.0 to 291.4)

Serotype 5, 1 Month Post Vax 2

Title	Measurements
	OG00095(67.1 to 133.2) OG001223(180.7 to 276.3) OG00280(59.7 to 108.3)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00029(20.3 to 42.5) OG00172(54.6 to 95.1) OG00241(30.3 to 56.2)

Serotype 6A, 1 Month Post Vax 2

Title	Measurements
	OG0002120(1614.1 to 2783.9) OG0011307(1021.4 to 1672.8) OG002933(682.1 to 1276.2)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000304(207.7 to 446.3) OG001266(195.2 to 362.6) OG002115(79.3 to 166.3)

Serotype 6B, 1 Month Post Vax 2

Title	Measurements
	OG0001683(1253.6 to 2258.3) OG0011232(965.9 to 1570.4) OG002740(534.8 to 1024.2)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000847(590.8 to 1214.8) OG001637(476.3 to 851.6) OG002352(244.8 to 505.5)

Serotype 7F, 1 Month Post Vax 2

Title	Measurements
	OG000306(201.8 to 462.5) OG001667(531.5 to 836.8) OG002131(87.8 to 496.9)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000237(152.2 to 369.9) OG001412(313.2 to 541.5) OG002148(101.4 to 215.1)

Serotype 9V, 1 Month Post Vax 2

Title	Measurements
	OG000385(252.6 to 586.8) OG001419(298.6 to 588.0) OG002122(80.0 to 186.1)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG000221(139.8 to 350.8) OG001224(155.9 to 321.6) OG002139(90.6 to 213.1)

Serotype 14, 1 Month Post Vax 2

Title	Measurements
	OG000434(311.6 to 605.6) OG001639(487.8 to 836.3) OG002426(312.7 to 580.5)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000380(273.4 to 528.8) OG001406(306.7 to 537.0) OG002388(290.7 to 517.2)

Serotype 18C, 1 Month Post Vax 2

Title	Measurements
	OG000972(732.4 to 1290.1) OG0011092(879.6 to 1356.2) OG002549(395.9 to 761.1)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000373(255.6 to 544.2) OG001513(389.6 to 676.7) OG002331(235.3 to 467.0)

Serotype 19A, 1 Month Post Vax 2

Title	Measurements
	OG000365(295.0 to 450.7) OG001513(445.6 to 590.5) OG002282(230.3 to 344.4)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000213(163.6 to 276.3) OG001295(246.6 to 352.7) OG002167(132.0 to 210.5)

Serotype 19F, 1 Month Post Vax 2

Title	Measurements
	OG000493(365.0 to 664.7) OG001835(685.5 to 1015.9) OG002264(196.3 to 355.8)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000255(180.5 to 360.8) OG001425(340.9 to 529.2) OG002197(146.4 to 266.2)

Serotype 23F, 1 Month Post Vax 2

Title	Measurements
	OG000543(392.9 to 749.4) OG001218(164.8 to 288.0) OG002109(76.4 to 156.2)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000108(71.9 to 162.3) OG00163(46.4 to 84.5) OG00238(27.1 to 52.2)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.4	2-Sided	95	0.32	0.46	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.3	2-Sided	95	0.30	0.41	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.44	0.61	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.2	2-Sided	95	0.17	0.25	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.2	2-Sided	95	0.18	0.24	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.4	2-Sided	95	0.31	0.41	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.2	2-Sided	95	0.19	0.32	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.3	2-Sided	95	0.22	0.33	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.2	2-Sided	95	0.17	0.30	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.3	2-Sided	95	0.25	0.39	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.3	2-Sided	95	0.27	0.38	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.44	0.60	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.1	2-Sided	95	0.10	0.20	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.2	2-Sided	95	0.17	0.25	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.1	2-Sided	95	0.09	0.16	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.41	0.62	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.43	0.62	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.38	0.59	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.8	2-Sided	95	0.60	1.00	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.51	0.75	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.1	2-Sided	95	0.86	1.46	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.41	0.80	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.39	0.73	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.1	2-Sided	95	0.78	1.67	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.9	2-Sided	95	0.71	1.08	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.54	0.75	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.9	2-Sided	95	0.78	1.06	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.4	2-Sided	95	0.29	0.51	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.39	0.56	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.53	0.69	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.49	0.69	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.52	0.63	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.53	0.66	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.42	0.64	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.44	0.60	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.7	2-Sided	95	0.63	0.88	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.2	2-Sided	95	0.15	0.26	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.3	2-Sided	95	0.23	0.35	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.3	2-Sided	95	0.28	0.43	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, 1 Month Post Vax 2

Title	Measurements
	OG00080(65.0 to 97.7) OG00134(27.2 to 43.7)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00039(31.1 to 48.2) OG00122(17.4 to 27.6)

Serotype 3, 1 Month Post Vax 2

Title	Measurements
	OG00050(42.1 to 59.2) OG00132(26.1 to 38.9)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00020(16.5 to 23.6) OG00116(13.2 to 19.1)

Serotype 4, 1 Month Post Vax 2

Title	Measurements
	OG000437(332.0 to 576.3) OG001237(173.5 to 325.1)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000311(238.1 to 407.1) OG001186(138.3 to 250.2)

Serotype 5, 1 Month Post Vax 2

Title	Measurements
	OG00062(48.1 to 79.4) OG00149(37.4 to 63.7)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00058(45.0 to 74.4) OG00142(31.7 to 54.8)

Serotype 6A, 1 Month Post Vax 2

Title	Measurements
	OG0001088(843.2 to 1404.7) OG001569(421.8 to 768.5)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000257(192.4 to 342.9) OG001133(97.4 to 182.1)

Serotype 6B, 1 Month Post Vax 2

Title	Measurements
	OG0001516(1173.7 to 1957.5) OG001781(574.8 to 1061.9)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000561(421.4 to 746.9) OG001381(282.6 to 514.5)

Serotype 7F, 1 Month Post Vax 2

Title	Measurements
	OG000233(166.5 to 324.8) OG001135(93.2 to 194.5)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000173(125.9 to 239.1) OG001117(82.8 to 165.4)

Serotype 9V, 1 Month Post Vax 2

Title	Measurements
	OG000166(113.8 to 241.5) OG00191(62.0 to 133.3)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG00083(56.2 to 121.9) OG00173(49.9 to 105.9)

Serotype 14, 1 Month Post Vax 2

Title	Measurements
	OG000216(163.8 to 284.3) OG001199(146.9 to 270.8)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000209(159.5 to 272.9) OG001244(184.5 to 321.9)

Serotype 18C, 1 Month Post Vax 2

Title	Measurements
	OG0001015(832.6 to 1237.6) OG001523(395.1 to 693.5)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000553(446.5 to 685.6) OG001366(277.2 to 482.9)

Serotype 19A, 1 Month Post Vax 2

Title	Measurements
	OG000356(297.6 to 425.6) OG001255(207.8 to 313.7)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000228(189.1 to 276.1) OG001182(147.7 to 225.2)

Serotype 19F, 1 Month Post Vax 2

Title	Measurements
	OG000349(274.7 to 444.5) OG001178(134.1 to 235.0)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000274(214.2 to 350.8) OG001158(119.1 to 210.6)

Serotype 23F, 1 Month Post Vax 2

Title	Measurements
	OG000324(250.8 to 419.8) OG001113(82.4 to 154.8)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000102(77.0 to 135.0) OG00146(33.9 to 61.7)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.42	0.56	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.56	0.72	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.35	0.45	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.44	0.57	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.60	0.85	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.8	2-Sided	95	0.63	0.97	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.81	1.08	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.74	0.99	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.19	0.29	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.19	0.29	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations	No	Superiority or Other
OG000	Serotype 6B: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.31	0.45	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.40	0.59	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.58	0.96	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations	No	Superiority or Other
OG001	Serotype 7F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.67	1.13	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.37	0.67	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.8	2-Sided	95	0.57	1.12	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.0	2-Sided	95	0.85	1.09	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.2	2-Sided	95	1.04	1.43	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.48	0.62	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.59	0.83	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.57	0.72	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.65	0.79	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.8	2-Sided	95	0.66	0.93	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.75	1.05	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.27	0.37	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations	No	Superiority or Other
OG001	Serotype 23F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.34	0.48	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, Pre Vax 2

Title	Measurements
	OG00052(38.2 to 69.5) OG00156(44.4 to 70.6) OG00244(33.0 to 57.7)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00052(39.6 to 69.0) OG00150(39.7 to 63.9) OG00234(26.2 to 45.1)

Serotype 3, Pre Vax 2

Title	Measurements
	OG00019(14.5 to 24.1) OG00123(18.6 to 28.1) OG00226(20.3 to 32.4)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00018(14.2 to 22.3) OG00126(21.4 to 31.6) OG00218(14.7 to 22.4)

Serotype 4, Pre Vax 2

Title	Measurements
	OG000710(504.4 to 998.7) OG001591(437.9 to 798.0) OG002350(242.0 to 506.6)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000376(264.2 to 534.0) OG001414(312.3 to 548.2) OG002209(144.6 to 302.1)

Serotype 5, Pre Vax 2

Title	Measurements
	OG00039(26.2 to 56.7) OG00166(48.9 to 87.8) OG00249(36.4 to 67.1)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00029(20.4 to 42.1) OG00173(55.3 to 96.4) OG00243(31.9 to 58.2)

Serotype 6A, Pre Vax 2

Title	Measurements
	OG000540(347.1 to 838.8) OG001656(484.0 to 888.4) OG00285(56.3 to 127.7)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000331(227.1 to 483.3) OG001251(183.4 to 343.3) OG002108(74.7 to 157.3)

Serotype 6B, Pre Vax 2

Title	Measurements
	OG000459(292.2 to 719.9) OG001430(304.8 to 605.6) OG002192(128.4 to 286.0)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000781(529.8 to 1150.8) OG001580(427.9 to 786.8) OG002298(203.8 to 435.6)

Serotype 7F, Pre Vax 2

Title	Measurements
	OG000146(89.4 to 237.1) OG001133(92.4 to 191.0) OG00271(46.9 to 107.6)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000244(155.7 to 383.4) OG001414(313.8 to 546.5) OG002146(99.7 to 212.8)

Serotype 9V, Pre Vax 2

Title	Measurements
	OG00096(58.3 to 158.4) OG00179(53.2 to 116.2) OG00250(32.4 to 78.5)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG000201(125.8 to 320.2) OG001212(147.4 to 306.4) OG002147(95.8 to 226.8)

Serotype 14, Pre Vax 2

Title	Measurements
	OG000241(159.6 to 364.0) OG001290(208.6 to 403.1) OG002302(214.2 to 425.3)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000383(274.1 to 534.2) OG001420(317.0 to 556.1) OG002367(272.9 to 493.4)

Serotype 18C, Pre Vax 2

Title	Measurements
	OG000403(273.8 to 592.0) OG001462(346.1 to 615.8) OG002339(236.2 to 487.4)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000398(274.1 to 579.1) OG001513(389.5 to 676.1) OG002349(247.8 to 492.2)

Serotype 19A, Pre Vax 2

Title	Measurements
	OG000203(151.3 to 271.8) OG001209(170.3 to 257.6) OG002153(117.3 to 199.5)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000253(197.2 to 325.7) OG001296(248.3 to 353.0) OG002169(133.0 to 214.6)

Serotype 19F, Pre Vax 2

Title	Measurements
	OG000114(72.7 to 177.5) OG001183(135.0 to 247.7) OG002127(89.7 to 180.1)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000238(165.2 to 341.7) OG001419(334.2 to 524.2) OG002190(139.8 to 258.7)

Serotype 23F, Pre Vax 2

Title	Measurements
	OG00090(58.5 to 139.9) OG00190(65.4 to 123.6) OG00230(21.2 to 42.1)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000104(67.9 to 158.6) OG00166(48.7 to 88.9) OG00236(26.3 to 50.6)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.0	2-Sided	95	0.85	1.22	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.79	1.02	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.8	2-Sided	95	0.69	0.90	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.0	2-Sided	95	0.82	1.10	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.1	2-Sided	95	0.98	1.32	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.62	0.81	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.41	0.69	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.60	0.82	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.47	0.76	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.8	2-Sided	95	0.67	0.87	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.1	2-Sided	95	0.96	1.30	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.75	1.02	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.48	0.79	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.32	0.46	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.3	2-Sided	95	0.94	1.75	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.7	2-Sided	95	1.32	2.19	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.4	2-Sided	95	1.14	1.60	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.6	2-Sided	95	1.20	2.01	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.7	2-Sided	95	1.24	2.26	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	3.1	2-Sided	95	2.26	4.30	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.0	2-Sided	95	1.53	2.75	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.1	2-Sided	95	1.48	2.95	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.7	2-Sided	95	1.97	3.70	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.9	2-Sided	95	1.99	4.29	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.6	2-Sided	95	1.23	2.05	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.4	2-Sided	95	1.18	1.78	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.2	2-Sided	95	1.04	1.42	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.0	2-Sided	95	0.82	1.19	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.1	2-Sided	95	0.96	1.29	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.0	2-Sided	95	0.89	1.20	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.2	2-Sided	95	1.07	1.46	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.4	2-Sided	95	1.24	1.61	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.1	2-Sided	95	0.96	1.27	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rises	2.1	2-Sided	95	1.56	2.80	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations	No	Superiority or Other
OG001	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.3	2-Sided	95	1.82	2.88	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.5	2-Sided	95	1.18	1.90	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.1	2-Sided	95	0.89	1.48	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.63	0.85	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.2	2-Sided	95	0.99	1.51	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, Pre Vax 2

Title	Measurements
	OG00033(26.4 to 41.1) OG00121(17.1 to 26.9)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00038(30.7 to 47.5) OG00122(17.5 to 27.8)

Serotype 3, Pre Vax 2

Title	Measurements
	OG00016(13.2 to 19.4) OG00116(13.0 to 19.4)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00019(16.2 to 23.2) OG00116(13.3 to 19.4)

Serotype 4, Pre Vax 2

Title	Measurements
	OG000129(89.0 to 186.9) OG00173(50.4 to 104.7)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000267(198.8 to 358.8) OG001177(129.9 to 240.0)

Serotype 5, Pre Vax 2

Title	Measurements
	OG00032(25.0 to 41.4) OG00124(18.0 to 30.8)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00057(44.5 to 73.2) OG00142(32.2 to 55.6)

Serotype 6A, Pre Vax 2

Title	Measurements
	OG000279(203.4 to 383.4) OG00158(41.9 to 81.1)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000256(191.2 to 341.9) OG001113(82.5 to 155.2)

Serotype 6B, Pre Vax 2

Title	Measurements
	OG000403(290.6 to 558.3) OG001186(131.1 to 264.3)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000511(376.9 to 693.4) OG001361(263.4 to 495.7)

Serotype 7F, Pre Vax 2

Title	Measurements
	OG00066(46.3 to 95.3) OG00166(45.5 to 95.0)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000175(127.1 to 240.3) OG001111(78.4 to 157.4)

Serotype 9V, Pre Vax 2

Title	Measurements
	OG00040(27.6 to 59.1) OG00128(19.7 to 40.6)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG00076(51.6 to 112.9) OG00169(47.3 to 100.9)

Serotype 14, Pre Vax 2

Title	Measurements
	OG000130(96.1 to 176.2) OG001144(104.7 to 198.7)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000204(155.6 to 268.5) OG001240(180.7 to 319.3)

Serotype 18C, Pre Vax 2

Title	Measurements
	OG000436(340.9 to 556.7) OG001271(197.8 to 371.7)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000545(438.2 to 678.0) OG001360(272.5 to 475.9)

Serotype 19A, Pre Vax 2

Title	Measurements
	OG000185(152.8 to 222.9) OG001124(97.4 to 158.3)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000235(196.4 to 282.2) OG001181(146.7 to 223.8)

Serotype 19F, Pre Vax 2

Title	Measurements
	OG000121(91.1 to 160.0) OG00184(61.6 to 115.4)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000261(204.9 to 333.7) OG001159(119.0 to 211.4)

Serotype 23F, Pre Vax 2

Title	Measurements
	OG00060(44.5 to 81.1) OG00130(22.3 to 41.0)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000104(78.0 to 137.4) OG00146(33.9 to 61.8)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.2	2-Sided	95	1.03	1.31	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.0	2-Sided	95	0.91	1.16	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.2	2-Sided	95	1.07	1.37	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.0	2-Sided	95	0.91	1.13	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.1	2-Sided	95	1.60	2.68	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.4	2-Sided	95	1.82	3.24	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.8	2-Sided	95	1.55	2.03	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.8	2-Sided	95	1.54	2.09	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.79	1.07	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.9	2-Sided	95	1.48	2.55	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.3	2-Sided	95	1.05	1.53	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.9	2-Sided	95	1.50	2.51	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.6	2-Sided	95	1.98	3.50	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.7	2-Sided	95	1.31	2.18	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.9	2-Sided	95	1.37	2.61	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.4	2-Sided	95	1.76	3.38	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.6	2-Sided	95	1.33	1.86	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.7	2-Sided	95	1.38	2.01	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.3	2-Sided	95	1.10	1.42	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.3	2-Sided	95	1.14	1.55	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.3	2-Sided	95	1.14	1.43	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.5	2-Sided	95	1.28	1.67	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	2.2	2-Sided	95	1.80	2.60	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.9	2-Sided	95	1.53	2.31	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.7	2-Sided	95	1.44	2.06	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.5	2-Sided	95	1.24	1.84	Confidence intervals (CIs) are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, 1 Month Post Vax 1

Title	Measurements
	OG000229(176.7 to 295.9) OG001228(185.8 to 280.7) OG002147(112.6 to 192.0)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00054(40.6 to 71.4) OG00147(37.5 to 60.0) OG00235(26.6 to 46.3)

Serotype 3, 1 Month Post Vax 1

Title	Measurements
	OG00075(59.1 to 95.5) OG00175(61.6 to 91.6) OG00285(69.0 to 103.9)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00019(14.8 to 23.3) OG00127(22.5 to 32.8) OG00218(14.8 to 22.5)

Serotype 4, 1 Month Post Vax 1

Title	Measurements
	OG0002546(1908.6 to 3395.8) OG0012575(2075.2 to 3195.9) OG0021406(1026.6 to 1926.5)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000346(242.6 to 493.7) OG001405(304.4 to 538.3) OG002184(127.1 to 267.4)

Serotype 5, 1 Month Post Vax 1

Title	Measurements
	OG000153(101.6 to 229.5) OG001255(190.1 to 341.4) OG002145(106.8 to 197.9)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00026(18.5 to 37.8) OG00169(52.4 to 91.8) OG00245(33.6 to 61.0)

Serotype 6A, 1 Month Post Vax 1

Title	Measurements
	OG0002757(2027.3 to 3750.3) OG0013022(2356.7 to 3875.6) OG002335(227.3 to 494.8)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000286(195.1 to 418.1) OG001235(171.4 to 320.9) OG002105(73.1 to 152.2)

Serotype 6B, 1 Month Post Vax 1

Title	Measurements
	OG0001739(1176.0 to 2570.2) OG0011969(1512.1 to 2562.7) OG002767(545.3 to 1080.0)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000855(595.2 to 1227.5) OG001697(523.9 to 926.4) OG002319(220.5 to 462.1)

Serotype 7F, 1 Month Post Vax 1

Title	Measurements
	OG000906(590.6 to 1388.7) OG0011459(1147.2 to 1855.1) OG002365(243.8 to 546.8)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000231(148.8 to 359.6) OG001398(301.1 to 527.0) OG002143(97.9 to 208.2)

Serotype 9V, 1 Month Post Vax 1

Title	Measurements
	OG0001055(740.6 to 1502.7) OG001801(589.0 to 1090.0) OG002294(192.2 to 449.9)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG000203(127.4 to 322.0) OG001224(155.1 to 322.3) OG002127(82.5 to 196.0)

Serotype 14, 1 Month Post Vax 1

Title	Measurements
	OG000614(409.0 to 921.9) OG001727(527.6 to 1000.7) OG002748(535.4 to 1045.9)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000387(277.1 to 540.7) OG001435(329.4 to 575.6) OG002391(291.9 to 524.8)

Serotype 18C, 1 Month Post Vax 1

Title	Measurements
	OG0001603(1153.7 to 2226.2) OG0011614(1230.2 to 2117.7) OG002888(639.0 to 1233.2)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000409(281.0 to 596.0) OG001560(424.2 to 739.8) OG002323(227.9 to 457.0)

Serotype 19A, 1 Month Post Vax 1

Title	Measurements
	OG000698(522.4 to 932.2) OG001781(662.0 to 920.4) OG002380(296.6 to 486.6)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000243(185.7 to 319.1) OG001310(260.8 to 369.0) OG002162(126.7 to 207.7)

Serotype 19F, 1 Month Post Vax 1

Title	Measurements
	OG000530(361.7 to 775.7) OG001845(661.8 to 1079.9) OG002423(302.2 to 591.4)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000239(166.7 to 342.6) OG001416(333.0 to 519.7) OG002180(131.7 to 245.7)

Serotype 23F, 1 Month Post Vax 1

Title	Measurements
	OG000339(219.9 to 521.8) OG001367(268.3 to 501.2) OG00272(49.1 to 104.7)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000105(69.5 to 159.3) OG00170(52.0 to 95.0) OG00239(27.6 to 53.8)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.2	2-Sided	95	0.19	0.29	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.17	0.25	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.20	0.29	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.20	0.30	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.31	0.42	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.18	0.26	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.1	2-Sided	95	0.10	0.18	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.12	0.20	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.1	2-Sided	95	0.10	0.18	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.13	0.22	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.22	0.33	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.25	0.38	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.1	2-Sided	95	0.08	0.14	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.1	2-Sided	95	0.06	0.10	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.22	0.46	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.40	0.60	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.29	0.43	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.29	0.59	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.17	0.38	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.21	0.36	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.27	0.56	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.13	0.28	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.20	0.39	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.28	0.67	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.48	0.83	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.49	0.74	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.42	0.65	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.20	0.32	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.28	0.43	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.29	0.45	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.30	0.41	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.35	0.45	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.36	0.51	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.35	0.58	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.39	0.62	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.34	0.54	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.23	0.42	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.2	2-Sided	95	0.15	0.24	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.42	0.69	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, 1 Month Post Vax 1

Title	Measurements
	OG00092(72.4 to 118.0) OG00153(41.5 to 68.2)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00039(31.5 to 48.6) OG00122(17.5 to 28.0)

Serotype 3, 1 Month Post Vax 1

Title	Measurements
	OG00052(42.2 to 63.2) OG00151(41.5 to 63.5)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00019(16.2 to 23.4) OG00116(13.1 to 19.1)

Serotype 4, 1 Month Post Vax 1

Title	Measurements
	OG000511(374.5 to 697.2) OG001216(151.2 to 308.2)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000271(203.9 to 361.3) OG001185(136.2 to 249.9)

Serotype 5, 1 Month Post Vax 1

Title	Measurements
	OG00084(64.7 to 108.8) OG00142(31.6 to 55.2)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00058(45.6 to 75.0) OG00142(31.9 to 55.2)

Serotype 6A, 1 Month Post Vax 1

Title	Measurements
	OG000975(715.1 to 1328.4) OG001106(75.2 to 149.1)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000264(197.8 to 353.4) OG001115(84.3 to 158.2)

Serotype 6B, 1 Month Post Vax 1

Title	Measurements
	OG0001331(981.1 to 1806.1) OG001465(333.3 to 648.1)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000553(411.3 to 743.9) OG001396(289.7 to 540.2)

Serotype 7F, 1 Month Post Vax 1

Title	Measurements
	OG000328(233.5 to 459.8) OG001195(134.4 to 281.9)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000165(119.3 to 227.8) OG001112(79.2 to 159.1)

Serotype 9V, 1 Month Post Vax 1

Title	Measurements
	OG000193(131.4 to 282.8) OG001102(68.2 to 152.2)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG00082(55.3 to 121.8) OG00169(46.9 to 101.2)

Serotype 14, 1 Month Post Vax 1

Title	Measurements
	OG000241(179.4 to 325.0) OG001280(203.3 to 384.3)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000205(155.8 to 270.6) OG001236(175.5 to 318.0)

Serotype 18C, 1 Month Post Vax 1

Title	Measurements
	OG000946(749.2 to 1195.4) OG001555(405.8 to 759.9)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000544(435.5 to 679.5) OG001370(276.9 to 495.3)

Serotype 19A, 1 Month Post Vax 1

Title	Measurements
	OG000381(312.9 to 462.9) OG001199(157.3 to 251.4)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000232(192.7 to 279.3) OG001180(145.9 to 222.1)

Serotype 19F, 1 Month Post Vax 1

Title	Measurements
	OG000407(312.1 to 531.7) OG001238(177.4 to 320.2)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000281(219.7 to 358.5) OG001158(118.2 to 211.0)

Serotype 23F, 1 Month Post Vax 1

Title	Measurements
	OG000173(125.5 to 239.6) OG00148(35.2 to 65.6)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000106(79.7 to 141.5) OG00145(33.0 to 60.2)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.36	0.50	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.36	0.48	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.33	0.44	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.26	0.37	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.42	0.68	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.64	1.14	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.60	0.82	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.0	2-Sided	95	0.86	1.18	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.3	2-Sided	95	0.22	0.33	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	1.1	2-Sided	95	0.81	1.46	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.34	0.51	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.66	1.09	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.5	2-Sided	95	0.37	0.68	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.43	0.77	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.4	2-Sided	95	0.30	0.60	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.47	0.98	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.72	1.01	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.8	2-Sided	95	0.71	1.00	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.50	0.66	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.56	0.80	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.54	0.69	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.78	1.05	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.59	0.80	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.7	2-Sided	95	0.53	0.83	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.6	2-Sided	95	0.51	0.74	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.	Geometric mean fold rise	0.9	2-Sided	95	0.75	1.15	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, Pre Vax 1

Title	Measurements
	OG0007(5.6 to 7.9) OG0016(5.4 to 7.1) OG0027(6.2 to 8.9)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00054(40.8 to 70.4) OG00152(40.9 to 65.5) OG00236(27.0 to 46.8)

Serotype 3, Pre Vax 1

Title	Measurements
	OG0006(5.0 to 6.9) OG0016(5.3 to 7.0) OG0027(5.6 to 7.7)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00019(14.9 to 23.5) OG00127(22.1 to 32.3) OG00217(14.0 to 21.3)

Serotype 4, Pre Vax 1

Title	Measurements
	OG00024(14.7 to 40.3) OG00136(23.8 to 54.0) OG00231(20.3 to 47.2)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000314(208.6 to 472.1) OG001323(233.9 to 445.7) OG002170(115.4 to 249.2)

Serotype 5, Pre Vax 1

Title	Measurements
	OG0005(4.2 to 5.3) OG0016(5.2 to 6.9) OG0026(4.9 to 6.6)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00029(20.4 to 41.4) OG00175(57.4 to 99.2) OG00243(31.4 to 57.6)

Serotype 6A, Pre Vax 1

Title	Measurements
	OG00021(13.5 to 31.9) OG00117(12.4 to 24.6) OG00214(10.1 to 20.4)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000313(210.4 to 464.4) OG001214(153.1 to 298.7) OG00294(64.0 to 137.6)

Serotype 6B, Pre Vax 1

Title	Measurements
	OG00035(20.6 to 58.4) OG00124(16.7 to 35.7) OG00226(17.3 to 40.1)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000720(474.8 to 1090.7) OG001522(378.0 to 719.8) OG002292(197.3 to 431.9)

Serotype 7F, Pre Vax 1

Title	Measurements
	OG0007(5.4 to 10.0) OG0018(6.3 to 10.5) OG0027(5.7 to 9.5)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000238(152.5 to 370.7) OG001384(290.3 to 508.9) OG002143(97.6 to 208.7)

Serotype 9V, Pre Vax 1

Title	Measurements
	OG00015(9.5 to 22.5) OG00115(10.7 to 21.5) OG00218(11.9 to 26.0)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG000187(116.1 to 301.9) OG001192(130.6 to 283.3) OG002119(76.6 to 185.1)

Serotype 14, Pre Vax 1

Title	Measurements
	OG00027(17.6 to 42.5) OG00134(23.1 to 48.6) OG00246(30.9 to 67.1)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000350(249.6 to 489.5) OG001385(286.5 to 518.5) OG002366(271.3 to 494.2)

Serotype 18C, Pre Vax 1

Title	Measurements
	OG00020(13.5 to 29.7) OG00125(17.8 to 33.8) OG00233(22.9 to 47.5)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000400(274.2 to 584.1) OG001546(415.3 to 718.0) OG002324(229.8 to 455.8)

Serotype 19A, Pre Vax 1

Title	Measurements
	OG00020(14.6 to 28.6) OG00125(19.1 to 32.9) OG00221(15.9 to 28.5)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000245(188.5 to 319.5) OG001327(273.7 to 391.0) OG002162(125.9 to 209.4)

Serotype 19F, Pre Vax 1

Title	Measurements
	OG00020(13.1 to 29.0) OG00124(17.3 to 33.4) OG00216(11.7 to 22.5)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000237(165.0 to 340.7) OG001415(332.9 to 516.2) OG002186(136.5 to 253.0)

Serotype 23F, Pre Vax 1

Title	Measurements
	OG00010(7.0 to 13.0) OG0019(7.1 to 11.2) OG0027(5.8 to 8.9)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000114(75.4 to 172.9) OG00159(43.9 to 80.6) OG00234(24.2 to 47.1)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	8.0	2-Sided	95	6.05	10.67	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	8.3	2-Sided	95	6.65	10.45	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	4.8	2-Sided	95	3.71	6.14	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	3.2	2-Sided	95	2.59	3.91	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	4.4	2-Sided	95	3.67	5.26	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.6	2-Sided	95	2.20	3.14	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.9	2-Sided	95	7.80	21.34	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	9.0	2-Sided	95	6.26	12.92	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	5.5	2-Sided	95	3.71	8.07	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	6.2	2-Sided	95	4.35	8.80	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.6	2-Sided	95	9.71	16.30	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	7.5	2-Sided	95	5.59	10.02	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	15.1	2-Sided	95	9.56	23.81	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.3	2-Sided	95	8.66	17.38	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	6.5	2-Sided	95	4.29	9.89	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	20.8	2-Sided	95	12.59	34.24	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	21.4	2-Sided	95	14.56	31.46	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	11.1	2-Sided	95	7.24	17.01	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	32.2	2-Sided	95	19.75	52.57	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	47.2	2-Sided	95	34.00	65.43	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	19.4	2-Sided	95	12.95	29.17	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.8	2-Sided	95	7.79	21.13	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.6	2-Sided	95	8.56	18.68	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	6.8	2-Sided	95	4.54	10.10	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.8	2-Sided	95	8.16	20.02	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	11.5	2-Sided	95	8.15	16.23	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	8.0	2-Sided	95	5.75	11.25	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	20.0	2-Sided	95	12.99	30.76	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	22.3	2-Sided	95	16.50	30.06	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	9.8	2-Sided	95	7.07	13.63	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.0	2-Sided	95	8.82	16.34	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	13.0	2-Sided	95	10.21	16.66	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	7.6	2-Sided	95	5.86	9.94	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.2	2-Sided	95	8.05	18.34	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	17.2	2-Sided	95	12.77	23.24	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	11.5	2-Sided	95	8.01	16.45	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	12.0	2-Sided	95	7.89	18.19	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	6.7	2-Sided	95	5.02	8.92	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG002	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	4.7	2-Sided	95	3.52	6.29	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, Pre Vax 1

Title	Measurements
	OG00010(8.7 to 12.4) OG00110(7.9 to 11.5)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00038(30.9 to 47.9) OG00122(17.6 to 28.1)

Serotype 3, Pre Vax 1

Title	Measurements
	OG0009(7.7 to 11.0) OG00110(8.6 to 12.2)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00020(16.4 to 23.5) OG00116(12.9 to 18.7)

Serotype 4, Pre Vax 1

Title	Measurements
	OG00030(20.4 to 42.9) OG00127(19.0 to 38.7)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000238(176.8 to 319.4) OG001160(117.1 to 219.2)

Serotype 5, Pre Vax 1

Title	Measurements
	OG00012(9.3 to 14.6) OG00114(10.8 to 17.6)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00057(44.4 to 73.2) OG00143(32.7 to 56.7)

Serotype 6A, Pre Vax 1

Title	Measurements
	OG00022(16.0 to 29.7) OG00131(22.1 to 42.6)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000259(192.7 to 346.9) OG001108(78.4 to 148.3)

Serotype 6B, Pre Vax 1

Title	Measurements
	OG00079(54.1 to 113.9) OG001123(84.0 to 179.4)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000507(368.6 to 696.7) OG001385(278.9 to 531.9)

Serotype 7F, Pre Vax 1

Title	Measurements
	OG00023(16.4 to 32.1) OG00121(14.7 to 28.9)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000169(122.3 to 232.4) OG001115(81.7 to 163.2)

Serotype 9V, Pre Vax 1

Title	Measurements
	OG00021(14.4 to 29.9) OG00123(15.9 to 32.6)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG00075(50.5 to 111.3) OG00166(45.3 to 97.4)

Serotype 14, Pre Vax 1

Title	Measurements
	OG00070(49.9 to 97.8) OG00179(55.5 to 111.2)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000202(153.2 to 266.8) OG001224(167.0 to 299.6)

Serotype 18C, Pre Vax 1

Title	Measurements
	OG000131(95.8 to 178.3) OG001145(103.9 to 201.9)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000530(425.0 to 660.6) OG001368(277.8 to 488.9)

Serotype 19A, Pre Vax 1

Title	Measurements
	OG00079(62.4 to 101.1) OG00166(50.9 to 85.3)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000236(197.3 to 283.1) OG001175(141.8 to 216.8)

Serotype 19F, Pre Vax 1

Title	Measurements
	OG00046(33.2 to 62.9) OG00137(27.6 to 50.9)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000272(212.8 to 346.8) OG001151(112.6 to 201.6)

Serotype 23F, Pre Vax 1

Title	Measurements
	OG00014(11.1 to 18.4) OG00116(12.5 to 21.6)

Serotype 23F 1 Year Post Vax 2

Title	Measurements
	OG00099(74.0 to 131.6) OG00145(33.7 to 61.1)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	3.7	2-Sided	95	3.05	4.49	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.3	2-Sided	95	1.92	2.81	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.1	2-Sided	95	1.83	2.50	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.5	2-Sided	95	1.32	1.74	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	8.0	2-Sided	95	5.82	11.09	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	5.9	2-Sided	95	4.25	8.21	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	4.9	2-Sided	95	3.96	6.00	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	3.1	2-Sided	95	2.58	3.79	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	11.9	2-Sided	95	8.56	16.49	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	3.5	2-Sided	95	2.59	4.76	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	6.5	2-Sided	95	4.61	9.03	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	3.1	2-Sided	95	2.32	4.24	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	7.4	2-Sided	95	5.23	10.33	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	5.6	2-Sided	95	4.07	7.69	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	3.6	2-Sided	95	2.50	5.20	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.9	2-Sided	95	2.10	4.04	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.9	2-Sided	95	2.26	3.71	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.8	2-Sided	95	2.23	3.63	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	4.1	2-Sided	95	3.16	5.20	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.5	2-Sided	95	2.06	3.14	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	3.0	2-Sided	95	2.46	3.60	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.7	2-Sided	95	2.24	3.15	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	5.9	2-Sided	95	4.55	7.76	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	4.0	2-Sided	95	3.13	5.17	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	6.9	2-Sided	95	5.16	9.25	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG001	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.8	2-Sided	95	2.24	3.40	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00052(40.9 to 65.5) OG00136(27.1 to 46.7)

Serotype 3

Title	Measurements
	OG00027(22.2 to 32.3) OG00118(14.4 to 21.9)

Serotype 4

Title	Measurements
	OG000355(264.7 to 475.9) OG001183(127.7 to 263.2)

Serotype 5

Title	Measurements
	OG00076(58.0 to 99.7) OG00144(32.9 to 59.6)

Serotype 6A

Title	Measurements
	OG000225(163.6 to 308.3) OG001102(71.4 to 146.9)

Serotype 6B

Title	Measurements
	OG000593(441.4 to 797.3) OG001324(225.0 to 466.1)

Serotype 7F

Title	Measurements
	OG000412(313.1 to 541.2) OG001145(100.3 to 210.7)

Serotype 9V

Title	Measurements
	OG000221(154.2 to 316.0) OG001129(84.5 to 196.5)

Serotype 14

Title	Measurements
	OG000416(316.2 to 548.2) OG001383(286.9 to 510.6)

Serotype 18C

Title	Measurements
	OG000527(401.7 to 690.5) OG001337(240.7 to 471.7)

Serotype 19A

Title	Measurements
	OG000313(263.1 to 372.3) OG001170(134.4 to 214.8)

Serotype 19F

Title	Measurements
	OG000426(343.7 to 527.7) OG001195(145.1 to 262.1)

Serotype 23F

Title	Measurements
	OG00064(47.6 to 86.5) OG00135(25.6 to 48.6)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.5	2-Sided	95	1.02	2.08	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.5	2-Sided	95	1.14	1.99	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.9	2-Sided	95	1.22	3.06	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG001	Serotype 5: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.7	2-Sided	95	1.15	2.56	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	2.2	2-Sided	95	1.36	3.53	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.8	2-Sided	95	1.15	2.91	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000	Serotype 7F: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	2.8	2-Sided	95	1.80	4.44	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.7	2-Sided	95	0.99	2.96	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.1	2-Sided	95	0.73	1.62	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.6	2-Sided	95	1.02	2.39	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.8	2-Sided	95	1.38	2.45	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	2.2	2-Sided	95	1.53	3.12	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio	1.8	2-Sided	95	1.18	2.82	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS-23vPS/13vPnC)].	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00054(40.8 to 71.0) OG00136(27.1 to 46.7)

Serotype 3

Title	Measurements
	OG00019(15.0 to 23.5) OG00118(14.4 to 21.9)

Serotype 4

Title	Measurements
	OG000328(229.0 to 469.0) OG001183(127.7 to 263.2)

Serotype 5

Title	Measurements
	OG00029(20.4 to 41.4) OG00144(32.9 to 59.6)

Serotype 6A

Title	Measurements
	OG000316(216.5 to 461.2) OG001102(71.4 to 146.9)

Serotype 6B

Title	Measurements
	OG000785(540.6 to 1140.2) OG001324(225.0 to 466.1)

Serotype 7F

Title	Measurements
	OG000247(160.4 to 380.9) OG001145(100.3 to 210.7)

Serotype 9V

Title	Measurements
	OG000211(134.3 to 330.9) OG001129(84.5 to 196.5)

Serotype 14

Title	Measurements
	OG000379(273.6 to 526.2) OG001383(286.9 to 510.6)

Serotype 18C

Title	Measurements
	OG000393(271.3 to 569.3) OG001337(240.7 to 471.7)

Serotype 19A

Title	Measurements
	OG000244(189.1 to 314.1) OG001170(134.4 to 214.8)

Serotype 19F

Title	Measurements
	OG000256(182.4 to 359.0) OG001195(145.1 to 262.1)

Serotype 23F

Title	Measurements
	OG000110(73.9 to 165.0) OG00135(25.6 to 48.6)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.5	2-Sided	95	1.02	2.25	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.1	2-Sided	95	0.78	1.44	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.8	2-Sided	95	1.06	3.00	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.7	2-Sided	95	0.41	1.04	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	3.1	2-Sided	95	1.82	5.24	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	2.4	2-Sided	95	1.43	4.11	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.7	2-Sided	95	0.96	3.00	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.6	2-Sided	95	0.88	3.04	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.0	2-Sided	95	0.64	1.54	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.2	2-Sided	95	0.71	1.93	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.4	2-Sided	95	1.01	2.04	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.3	2-Sided	95	0.84	2.06	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	3.1	2-Sided	95	1.89	5.20	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00054(40.8 to 71.0) OG00152(40.9 to 65.5)

Serotype 3

Title	Measurements
	OG00019(15.0 to 23.5) OG00127(22.2 to 32.3)

Serotype 4

Title	Measurements
	OG000328(229.0 to 469.0) OG001355(264.7 to 475.9)

Serotype 5

Title	Measurements
	OG00029(20.4 to 41.4) OG00176(58.0 to 99.7)

Serotype 6A

Title	Measurements
	OG000316(216.5 to 461.2) OG001225(163.6 to 308.3)

Serotype 6B

Title	Measurements
	OG000785(540.6 to 1140.2) OG001593(441.4 to 797.3)

Serotype 7F

Title	Measurements
	OG000247(160.4 to 380.9) OG001412(313.1 to 541.2)

Serotype 9V

Title	Measurements
	OG000211(134.3 to 330.9) OG001221(154.2 to 316.0)

Serotype 14

Title	Measurements
	OG000379(273.6 to 526.2) OG001416(316.2 to 548.2)

Serotype 18C

Title	Measurements
	OG000393(271.3 to 569.3) OG001527(401.7 to 690.5)

Serotype 19A

Title	Measurements
	OG000244(189.1 to 314.1) OG001313(263.1 to 372.3)

Serotype 19F

Title	Measurements
	OG000256(182.4 to 359.0) OG001426(343.7 to 527.7)

Serotype 23F

Title	Measurements
	OG000110(73.9 to 165.0) OG00164(47.6 to 86.5)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.0	2-Sided	95	0.72	1.51	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.7	2-Sided	95	0.52	0.94	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.9	2-Sided	95	0.58	1.47	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.4	2-Sided	95	0.25	0.59	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.4	2-Sided	95	0.85	2.32	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.3	2-Sided	95	0.82	2.13	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.6	2-Sided	95	0.37	0.97	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.0	2-Sided	95	0.54	1.70	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.9	2-Sided	95	0.59	1.41	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.7	2-Sided	95	0.48	1.17	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.8	2-Sided	95	0.58	1.05	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	0.6	2-Sided	95	0.41	0.88	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.	Ratio of GMT	1.7	2-Sided	95	1.05	2.81	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 13vPnC/23vPS)]	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00038(30.9 to 47.9) OG00122(17.5 to 27.8)

Serotype 3

Title	Measurements
	OG00020(16.5 to 23.4) OG00116(13.3 to 19.2)

Serotype 4

Title	Measurements
	OG000265(200.8 to 348.5) OG001172(129.0 to 230.1)

Serotype 5

Title	Measurements
	OG00058(45.1 to 74.1) OG00142(32.2 to 55.6)

Serotype 6A

Title	Measurements
	OG000250(187.3 to 334.0) OG001115(84.5 to 156.8)

Serotype 6B

Title	Measurements
	OG000510(378.2 to 686.4) OG001381(281.9 to 513.9)

Serotype 7F

Title	Measurements
	OG000173(126.0 to 237.5) OG001115(81.6 to 160.9)

Serotype 9V

Title	Measurements
	OG00081(55.1 to 117.9) OG00168(47.4 to 98.5)

Serotype 14

Title	Measurements
	OG000202(154.6 to 265.0) OG001240(181.0 to 317.0)

Serotype 18C

Title	Measurements
	OG000540(435.5 to 668.5) OG001360(273.6 to 474.5)

Serotype 19A

Title	Measurements
	OG000232(193.2 to 278.1) OG001181(146.7 to 222.9)

Serotype 19F

Title	Measurements
	OG000277(218.6 to 351.7) OG001158(119.3 to 209.9)

Serotype 23F

Title	Measurements
	OG000103(78.0 to 135.0) OG00145(33.5 to 69.6)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.7	2-Sided	95	1.27	2.40	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.2	2-Sided	95	0.95	1.59	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.5	2-Sided	95	1.03	2.29	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.4	2-Sided	95	0.95	1.97	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	2.2	2-Sided	95	1.42	3.31	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.3	2-Sided	95	0.88	2.04	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.5	2-Sided	95	0.95	2.40	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.2	2-Sided	95	0.70	1.99	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	0.8	2-Sided	95	0.57	1.25	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.5	2-Sided	95	1.06	2.12	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.3	2-Sided	95	0.97	1.69	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	1.8	2-Sided	95	1.21	2.53	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale	Ratio of GMT	2.3	2-Sided	95	1.54	3.42	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/13vPnC - 23vPS/13vPnC)]	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00052(40.9 to 65.5) OG00145(34.5 to 59.8)

Serotype 3

Title	Measurements
	OG00027(22.2 to 32.3) OG00126(20.4 to 32.5)

Serotype 4

Title	Measurements
	OG000355(264.7 to 475.9) OG001332(231.8 to 476.2)

Serotype 5

Title	Measurements
	OG00076(58.0 to 99.7) OG00149(36.4 to 66.9)

Serotype 6A

Title	Measurements
	OG000225(163.6 to 308.3) OG00182(54.6 to 122.4)

Serotype 6B

Title	Measurements
	OG000593(441.4 to 797.3) OG001162(108.9 to 241.6)

Serotype 7F

Title	Measurements
	OG000412(313.1 to 541.2) OG00166(44.1 to 100.1)

Serotype 9V

Title	Measurements
	OG000221(154.2 to 316.0) OG00152(33.7 to 80.3)

Serotype 14

Title	Measurements
	OG000416(316.2 to 548.2) OG001302(214.2 to 425.3)

Serotype 18C

Title	Measurements
	OG000527(401.7 to 690.5) OG001319(222.5 to 457.3)

Serotype 19A

Title	Measurements
	OG000313(263.1 to 372.3) OG001153(117.3 to 199.5)

Serotype 19F

Title	Measurements
	OG000426(343.7 to 527.7) OG001125(88.8 to 176.5)

Serotype 23F

Title	Measurements
	OG00064(47.6 to 86.5) OG00130(21.2 to 42.1)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.1	2-Sided	95	0.80	1.63	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.0	2-Sided	95	0.77	1.39	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.1	2-Sided	95	0.68	1.69	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.5	2-Sided	95	1.03	2.31	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	2.7	2-Sided	95	1.66	4.55	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	3.7	2-Sided	95	2.25	5.94	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	6.2	2-Sided	95	3.85	9.98	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	4.2	2-Sided	95	2.43	7.40	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.4	2-Sided	95	0.89	2.13	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.7	2-Sided	95	1.06	2.57	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	2.0	2-Sided	95	1.50	2.78	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	3.4	2-Sided	95	2.30	5.04	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (13vPnC/23vPS to 23vPS) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	2.1	2-Sided	95	1.37	3.37	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(13vPnC/23vPS - 23vPS)]	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00036(27.1 to 46.7) OG00154(45.4 to 65.0)

Serotype 3

Title	Measurements
	OG00018(14.4 to 21.9) OG00121(18.1 to 24.9)

Serotype 4

Title	Measurements
	OG000183(127.7 to 263.2) OG001622(496.9 to 777.7)

Serotype 5

Title	Measurements
	OG00044(32.9 to 59.6) OG00152(40.9 to 64.8)

Serotype 6A

Title	Measurements
	OG000102(71.4 to 146.9) OG001597(466.8 to 764.7)

Serotype 6B

Title	Measurements
	OG000324(225.0 to 466.1) OG001420(320.2 to 552.0)

Serotype 7F

Title	Measurements
	OG000145(100.3 to 210.7) OG001133(99.6 to 177.8)

Serotype 9V

Title	Measurements
	OG000129(84.5 to 196.5) OG00185(62.7 to 115.4)

Serotype 14

Title	Measurements
	OG000383(286.9 to 510.6) OG001250(193.5 to 324.2)

Serotype 18C

Title	Measurements
	OG000337(240.7 to 471.7) OG001439(349.8 to 551.0)

Serotype 19A

Title	Measurements
	OG000170(134.4 to 214.8) OG001208(175.9 to 245.7)

Serotype 19F

Title	Measurements
	OG000195(145.1 to 262.1) OG001147(115.1 to 187.7)

Serotype 23F

Title	Measurements
	OG00035(25.6 to 48.6) OG00190(69.9 to 116.6)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.7	2-Sided	95	0.48	0.90	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.8	2-Sided	95	0.64	1.09	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.3	2-Sided	95	0.20	0.44	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.9	2-Sided	95	0.59	1.26	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.2	2-Sided	95	0.11	0.26	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.8	2-Sided	95	0.49	1.22	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.1	2-Sided	95	0.68	1.76	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.5	2-Sided	95	0.90	2.55	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.5	2-Sided	95	1.02	2.30	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.8	2-Sided	95	0.52	1.14	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.8	2-Sided	95	0.62	1.08	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.3	2-Sided	95	0.89	1.98	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (23vPs/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.4	2-Sided	95	0.26	0.59	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC - 13vPnC)].	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, Pre Vax 2

Title	Measurements
	OG00052(38.2 to 69.5)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00052(39.6 to 69.0)

Serotype 3, Pre Vax 2

Title	Measurements
	OG00019(14.5 to 24.1)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00018(14.2 to 22.3)

Serotype 4, Pre Vax 2

Title	Measurements
	OG000710(504.4 to 998.7)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000376(264.2 to 534.0)

Serotype 5, Pre Vax 2

Title	Measurements
	OG00039(26.2 to 56.7)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00029(20.4 to 42.1)

Serotype 6A, Pre Vax 2

Title	Measurements
	OG000540(347.1 to 838.8)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000331(227.1 to 483.3)

Serotype 6B, Pre Vax 2

Title	Measurements
	OG000459(292.2 to 719.9)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000781(529.8 to 1150.8)

Serotype 7F, Pre Vax 2

Title	Measurements
	OG000146(89.4 to 237.1)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000244(155.7 to 383.4)

Serotype 9V, Pre Vax 2

Title	Measurements
	OG00096(58.3 to 158.4)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG000201(125.8 to 320.2)

Serotype 14, Pre Vax 2

Title	Measurements
	OG000241(159.6 to 364.0)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000383(274.1 to 534.2)

Serotype 18C, Pre Vax 2

Title	Measurements
	OG000403(273.8 to 592.0)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000398(274.1 to 579.1)

Serotype 19A, Pre Vax 2

Title	Measurements
	OG000203(151.3 to 271.8)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000253(197.2 to 325.7)

Serotype 19F, Pre Vax 2

Title	Measurements
	OG000114(72.7 to 177.5)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000238(165.2 to 341.7)

Serotype 23F, Pre Vax 2

Title	Measurements
	OG00090(58.5 to 139.9)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000104(67.9 to 158.6)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.0	2-Sided	95	0.85	1.22	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.0	2-Sided	95	0.82	1.10	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.5	2-Sided	95	0.41	0.69	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.8	2-Sided	95	0.67	0.87	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.6	2-Sided	95	0.48	0.79	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.7	2-Sided	95	1.32	2.19	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.7	2-Sided	95	1.24	2.26	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.1	2-Sided	95	1.48	2.95	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.6	2-Sided	95	1.23	2.05	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.0	2-Sided	95	0.82	1.19	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.2	2-Sided	95	1.07	1.46	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.1	2-Sided	95	1.56	2.80	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.1	2-Sided	95	0.89	1.48	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00022(17.5 to 27.8) OG00133(26.6 to 41.3)

Serotype 3

Title	Measurements
	OG00016(13.3 to 19.2) OG00116(13.5 to 19.6)

Serotype 4

Title	Measurements
	OG000172(129.0 to 230.1) OG001123(85.4 to 177.6)

Serotype 5

Title	Measurements
	OG00042(32.2 to 55.6) OG00131(24.4 to 40.2)

Serotype 6A

Title	Measurements
	OG000115(84.5 to 156.8) OG001271(197.5 to 370.6)

Serotype 6B

Title	Measurements
	OG000381(281.9 to 513.9) OG001380(274.0 to 526.3)

Serotype 7F

Title	Measurements
	OG000115(81.6 to 160.9) OG00161(43.0 to 87.7)

Serotype 9V

Title	Measurements
	OG00068(47.4 to 98.5) OG00140(27.8 to 58.3)

Serotype 14

Title	Measurements
	OG000240(181.0 to 317.0) OG001126(93.0 to 170.7)

Serotype 18C

Title	Measurements
	OG000360(273.6 to 474.5) OG001439(343.4 to 559.9)

Serotype 19A

Title	Measurements
	OG000181(146.7 to 222.9) OG001183(151.3 to 220.7)

Serotype 19F

Title	Measurements
	OG000158(119.3 to 209.9) OG001115(87.4 to 151.3)

Serotype 23F

Title	Measurements
	OG00045(33.5 to 59.6) OG00159(43.7 to 79.4)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.7	2-Sided	95	0.48	0.92	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.0	2-Sided	95	0.76	1.28	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.4	2-Sided	95	0.88	2.22	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.4	2-Sided	95	0.93	1.95	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.4	2-Sided	95	0.27	0.66	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.0	2-Sided	95	0.64	1.56	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.9	2-Sided	95	1.14	3.04	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.7	2-Sided	95	1.01	2.85	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.9	2-Sided	95	1.26	2.87	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.8	2-Sided	95	0.57	1.19	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.0	2-Sided	95	0.75	1.31	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	1.4	2-Sided	95	0.93	2.04	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (23vPS/13vPnC to 13vPnC) was calculated by back transforming the mean difference between vaccine sequence/group on the logarithmic scale.	Ratio of GMT	0.8	2-Sided	95	0.50	1.15	CIs for the ratio are back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures [(23vPS/13vPnC-13vPnC)].	No	Superiority or Other

Title

Denominators

Categories

Serotype 1, Pre Vax 2

Title	Measurements
	OG00033(26.4 to 41.1)

Serotype 1, 1 Year Post Vax 2

Title	Measurements
	OG00038(30.7 to 47.5)

Serotype 3, Pre Vax 2

Title	Measurements
	OG00016(13.2 to 19.4)

Serotype 3, 1 Year Post Vax 2

Title	Measurements
	OG00019(16.2 to 23.2)

Serotype 4, Pre Vax 2

Title	Measurements
	OG000129(89.0 to 186.9)

Serotype 4, 1 Year Post Vax 2

Title	Measurements
	OG000267(198.8 to 358.8)

Serotype 5, Pre Vax 2

Title	Measurements
	OG00032(25.0 to 41.4)

Serotype 5, 1 Year Post Vax 2

Title	Measurements
	OG00057(44.5 to 73.2)

Serotype 6A, Pre Vax 2

Title	Measurements
	OG000279(203.4 to 383.4)

Serotype 6A, 1 Year Post Vax 2

Title	Measurements
	OG000256(191.2 to 341.9)

Serotype 6B, Pre Vax 2

Title	Measurements
	OG000403(290.6 to 558.3)

Serotype 6B, 1 Year Post Vax 2

Title	Measurements
	OG000511(376.9 to 693.4)

Serotype 7F, Pre Vax 2

Title	Measurements
	OG00066(46.3 to 95.3)

Serotype 7F, 1 Year Post Vax 2

Title	Measurements
	OG000175(127.1 to 240.3)

Serotype 9V, Pre Vax 2

Title	Measurements
	OG00040(27.6 to 59.1)

Serotype 9V, 1 Year Post Vax 2

Title	Measurements
	OG00076(51.6 to 112.9)

Serotype 14, Pre Vax 2

Title	Measurements
	OG000130(96.1 to 176.2)

Serotype 14, 1 Year Post Vax 2

Title	Measurements
	OG000204(155.6 to 268.5)

Serotype 18C, Pre Vax 2

Title	Measurements
	OG000436(340.9 to 556.7)

Serotype 18C, 1 Year Post Vax 2

Title	Measurements
	OG000545(438.2 to 678.0)

Serotype 19A, Pre Vax 2

Title	Measurements
	OG000185(152.8 to 222.9)

Serotype 19A, 1 Year Post Vax 2

Title	Measurements
	OG000235(196.4 to 282.2)

Serotype 19F, Pre Vax 2

Title	Measurements
	OG000121(91.1 to 160.0)

Serotype 19F, 1 Year Post Vax 2

Title	Measurements
	OG000261(204.9 to 333.7)

Serotype 23F, Pre Vax 2

Title	Measurements
	OG00060(44.5 to 81.1)

Serotype 23F, 1 Year Post Vax 2

Title	Measurements
	OG000104(78.0 to 137.4)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000	Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.2	2-Sided	95	1.03	1.31	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.2	2-Sided	95	1.07	1.37	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.1	2-Sided	95	1.60	2.68	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.8	2-Sided	95	1.55	2.03	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	0.9	2-Sided	95	0.79	1.07	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.3	2-Sided	95	1.05	1.53	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.6	2-Sided	95	1.98	3.50	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.9	2-Sided	95	1.37	2.61	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.6	2-Sided	95	1.33	1.86	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.3	2-Sided	95	1.10	1.42	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.3	2-Sided	95	1.14	1.43	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	2.2	2-Sided	95	1.80	2.60	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other
OG000	Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.	geometric mean fold rise	1.7	2-Sided	95	1.44	2.06	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00054(45.4 to 65.0) OG00145(34.5 to 59.8)

Serotype 3

Title	Measurements
	OG00021(18.1 to 24.9) OG00126(20.4 to 32.5)

Serotype 4

Title	Measurements
	OG000622(496.9 to 777.7) OG001332(231.8 to 476.2)

Serotype 5

Title	Measurements
	OG00052(40.9 to 64.8) OG00149(36.4 to 66.9)

Serotype 6A

Title	Measurements
	OG000597(466.8 to 764.7) OG00182(54.6 to 122.4)

Serotype 6B

Title	Measurements
	OG000420(320.2 to 552.0) OG001162(108.9 to 241.6)

Serotype 7F

Title	Measurements
	OG000133(99.6 to 177.8) OG00166(44.1 to 100.1)

Serotype 9V

Title	Measurements
	OG00085(62.7 to 115.4) OG00152(33.7 to 80.3)

Serotype 14

Title	Measurements
	OG000250(193.5 to 324.2) OG001302(214.2 to 425.3)

Serotype 18C

Title	Measurements
	OG000439(349.8 to 551.0) OG001319(222.5 to 457.3)

Serotype 19A

Title	Measurements
	OG000208(175.9 to 245.7) OG001153(117.3 to 199.5)

Serotype 19F

Title	Measurements
	OG000147(115.1 to 187.7) OG001125(88.8 to 176.5)

Serotype 23F

Title	Measurements
	OG00090(69.9 to 116.6) OG00130(21.2 to 42.1)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	1.2	2-Sided	95	0.87	1.64	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	0.8	2-Sided	95	0.63	1.08	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	1.9	2-Sided	95	1.25	2.80	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	1.0	2-Sided	95	0.71	1.53	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	7.3	2-Sided	95	4.67	11.44	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	2.6	2-Sided	95	1.61	4.17	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	2.0	2-Sided	95	1.22	3.29	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	1.6	2-Sided	95	0.96	2.77	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	0.8	2-Sided	95	0.54	1.28	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	1.4	2-Sided	95	0.92	2.07	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	1.4	2-Sided	95	1.01	1.83	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	1.2	2-Sided	95	0.77	1.78	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale.	Ratio	3.0	2-Sided	95	1.97	4.64	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00033(26.6 to 41.3) OG00121(16.8 to 26.5)

Serotype 3

Title	Measurements
	OG00016(13.5 to 19.6) OG00116(13.2 to 19.8)

Serotype 4

Title	Measurements
	OG000123(85.4 to 177.6) OG00168(47.0 to 96.9)

Serotype 5

Title	Measurements
	OG00031(24.4 to 40.2) OG00123(17.6 to 29.7)

Serotype 6A

Title	Measurements
	OG000271(197.5 to 370.6) OG00157(40.9 to 78.2)

Serotype 6B

Title	Measurements
	OG000380(274.0 to 526.3) OG001168(118.6 to 238.1)

Serotype 7F

Title	Measurements
	OG00061(43.0 to 87.7) OG00163(43.8 to 91.1)

Serotype 9V

Title	Measurements
	OG00040(27.8 to 58.3) OG00129(20.3 to 41.3)

Serotype 14

Title	Measurements
	OG000126(93.0 to 170.7) OG001140(101.7 to 192.7)

Serotype 18C

Title	Measurements
	OG000439(343.4 to 559.9) OG001271(197.8 to 371.7)

Serotype 19A

Title	Measurements
	OG000183(151.3 to 220.7) OG001122(96.0 to 155.9)

Serotype 19F

Title	Measurements
	OG000115(87.4 to 151.3) OG00186(63.2 to 115.9)

Serotype 23F

Title	Measurements
	OG00059(43.7 to 79.4) OG00130(22.3 to 41.0)

Group IDs	Group Description	Parameter Type	Parameter Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type
OG000 OG001	Serotype 1: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.6	2-Sided	95	1.15	2.15	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 3: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.0	2-Sided	95	0.76	1.32	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 4: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.8	2-Sided	95	1.09	3.05	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 5: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.4	2-Sided	95	0.95	1.96	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 6A: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	4.8	2-Sided	95	3.05	7.50	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 6B: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	2.3	2-Sided	95	1.40	3.64	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 7F: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.0	2-Sided	95	0.58	1.62	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 9V: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.4	2-Sided	95	0.83	2.32	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 14: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	0.9	2-Sided	95	0.58	1.40	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 18C: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.6	2-Sided	95	1.09	2.41	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 19A: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.5	2-Sided	95	1.10	2.03	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 19F: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.3	2-Sided	95	0.89	2.02	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other
OG000 OG001	Serotype 23F: Ratio of GMT (13vPnC to 23vPS) was calculated by back transforming the mean difference between vaccine group on the logarithmic scale	Ratio	1.9	2-Sided	95	1.27	2.97	CIs for the GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the measures [(13vPnC - 23vPS)].	No	Superiority or Other

Title

Denominators

Categories

Serotype 1

Title	Measurements
	OG00038(30.9 to 47.9) OG00122(17.5 to 27.8)

Serotype 3

Title	Measurements
	OG00020(16.5 to 23.4) OG00116(13.3 to 19.2)

Serotype 4

Title	Measurements
	OG000265(200.8 to 348.5) OG001172(129.0 to 230.1)

Serotype 5

Title	Measurements
	OG00058(45.1 to 74.1) OG00142(32.2 to 55.6)

Serotype 6A

Title	Measurements
	OG000250(187.3 to 334.0) OG001115(84.5 to 156.8)

Serotype 6B

Title	Measurements
	OG000510(378.2 to 686.4) OG001381(281.9 to 513.9)

Serotype 7F

Title	Measurements
	OG000173(126.0 to 237.5) OG001115(81.6 to 160.9)

Serotype 9V

Title	Measurements
	OG00081(55.1 to 117.9) OG00168(47.4 to 98.5)

Serotype 14

Title	Measurements
	OG000202(154.6 to 265.0) OG001240(181.0 to 317.0)

Serotype 18C

Title	Measurements
	OG000540(435.5 to 668.5) OG001360(273.6 to 474.5)

Serotype 19A

Title	Measurements
	OG000232(193.2 to 278.1) OG001181(146.7 to 222.9)

Serotype 19F

Title	Measurements
	OG000277(218.6 to 351.7) OG001158(119.3 to 209.9)

Serotype 23F

Title	Measurements
	OG000103(78.0 to 135.5) OG00145(33.5 to 59.6)